Results of a very recent study demonstrated that the SGLT2-i improves not only EAT but even interstitial myocardial fibrosis, aortic stiffness, and inflammation markers also in non-diabetic patients with heart failure with reduced ejection fraction [33]. This evidence concerns the gene SLC5A2 and heart failure.